GlassScriptPhysician profile
David A Liebergall
NPI 1619956240
$5,533.11
in general payments reported to CMS, 2019-2025
32 companies · $818 in 2025
The $818 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $879 · 2020: $193 · 2021: $682 · 2022: $558 · 2023: $1,106 · 2024: $1,297 · 2025: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,213 · Education: $7.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,213.44 |
| Education | $7.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,002.33 | 2022-2024 | |
| Alcon Vision LLC | $885.35 | 2019-2025 | Tryptyr, Acrysof Iq Vivity, Acrysof Iq Panoptix Uv Iol |
| Sun Pharmaceutical Industries INC. | $706.34 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $447.34 | 2022-2025 | Xiidra, Miebo, Envista Mx60 Iol |
| Coopervision INC. | $280.95 | 2021-2025 | Myday Contact Lens |
| Novartis Pharmaceuticals Corporation | $234.52 | 2019-2023 | |
| Oyster Point Pharma, INC. | $202.22 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Abbott Laboratories | $177.26 | 2019 | |
| Mallinckrodt Enterprises LLC | $164.26 | 2019 | |
| Ocular Therapeutix, INC. | $145.58 | 2023-2025 | Dextenza |
| Tarsus Pharmaceuticals, INC. | $111.78 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $104.13 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $100.93 | 2021-2024 | Acthar |
| Aerie Pharmaceuticals, INC. | $97.98 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $96.72 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $93.56 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $71.83 | 2019-2021 | |
| Shire North American Group INC | $67.41 | 2019 | |
| Harrow Eye, LLC | $62.72 | 2024-2025 | Vevye |
| Horizon Therapeutics Plc | $61.34 | 2022-2023 | Tepezza |
| Biotissue Holdings INC. | $58.14 | 2021-2023 | |
| Genzyme Corporation | $57.63 | 2019 | |
| Tearlab Corp | $42.90 | 2023 | Tearlab Osmolarity System |
| Janssen Biotech, INC. | $42.55 | 2023 | Simponi Aria, Simponi, Remicade |
| Rayner Intraocular Lenses Limited | $40.66 | 2022-2024 | Rayone Aspheric, Rayone Emv, Omidria |
| Dompe US, INC. | $38.89 | 2021-2024 | Oxervate |
| Astellas Pharma US INC | $35.23 | 2025 | Izervay |
| Johnson & Johnson Vision Care, INC. | $27.89 | 2019-2023 | Acuvue |
| Amgen INC. | $26.98 | 2024 | Tepezza |
| Rxsight INC | $23.16 | 2022 | |
| Novo Nordisk INC | $12.50 | 2019 | |
| Eyepoint US, INC. | $12.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Liebergall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.